Stocks Comparison
Pharma-Bio Serv vs Public Policy: revenue, profit, margins and growth compared
Pharma-Bio Serv brought in $9M of revenue in fiscal 2025, Public Policy $186.5M in fiscal 2025. Revenue changed by -5.3% at Pharma-Bio Serv and +24.7% at Public Policy on the year before, so Public Policy grew faster. Pharma-Bio Serv kept -1.1% of its revenue as net profit, Public Policy -20.9%. Free cash flow was -$221.5K at Pharma-Bio Serv and $24.8M at Public Policy.
Side by side, latest fiscal year
| PBSV | PPHC | |
|---|---|---|
| Fiscal year ended | FY2025 (October 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $9M | $186.5M |
| Revenue growth | -5.3% | +24.7% |
| Net income | -$100.5K | -$39M |
| Net margin | -1.1% | -20.9% |
| Free cash flow | -$221.5K | $24.8M |
| Free cash flow margin | -2.5% | 13.3% |
| Earnings per share (diluted) | -$0.00 | -$2.37 |
| Cash | $3.4M | $20.4M |
| Debt | n/a | $47M |
| Price to earnings | n/a | n/a |
| Market value | $8M | $282.3M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #508 of 587 · Industrials | #381 of 587 · Industrials |
Over the years
Questions about Pharma-Bio Serv and Public Policy
Which is bigger by revenue, Pharma-Bio Serv or Public Policy?
Public Policy is bigger by revenue: $186.5M in fiscal 2025, against $9M for Pharma-Bio Serv in fiscal 2025.
Which keeps more of its revenue as profit, Pharma-Bio Serv or Public Policy?
Pharma-Bio Serv had a net margin of -1.1% in fiscal 2025; Public Policy had -20.9% in fiscal 2025.
Which grew revenue faster, Pharma-Bio Serv or Public Policy?
In their latest fiscal years revenue changed by -5.3% at Pharma-Bio Serv and +24.7% at Public Policy.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.